The experimental vaccine of the University of Oxford and AstraZeneca Plc is the first to enter the final stages of clinical trials to evaluate its effectiveness in protecting individuals against the coronavirus infection, which has infected 9,4 million people and has kill 480,000 in the world since the end of December.
In the next phase, 10,260 adults and children will receive ChAdOx1 nCoV-19 vaccine licensed to AstraZeneca. The vaccine is also being examined in South Africa and Brazil, investing $100 million for one billion doses to mass production of India and other low and medium-income countries, through the Serum Institute of India (SII) and other countries.
The Oxford Vaccine Group anticipates the introduction of Covid-19 by the end of this year if the trial succeeds. It will be the fastest to progress from laboratory to regulatory approvals.
The Oxford Vaccine Group is not the only group to move to a vaccine at warp speed. There are 13 experimental trial vaccines and an additional 129 in the preclinical evaluation phase on 22 June, according to the World Health Organization.